- Home
- DOUG vs TLSA Comparison
DOUG vs TLSA Comparison
Compare DOUG & TLSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DOUG | TLSA |
|---|---|---|
| Founded | 1911 | 2013 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Building operators | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 162.3M | 155.3M |
| IPO Year | 2021 | 2017 |
Fundamental Metrics
Financial Performance| Metric | DOUG | TLSA |
|---|---|---|
| Price | $1.74 | $1.15 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 339.8K | 223.5K |
| Earning Date | 05-05-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 118.68 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $955,578,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.53 | $1.04 |
| 52 Week High | $3.19 | $2.60 |
Technical Indicators
Market Signals| Indicator | DOUG | TLSA |
|---|---|---|
| Relative Strength Index (RSI) | 47.69 | 41.66 |
| Support Level | $1.69 | $1.14 |
| Resistance Level | $1.86 | $1.44 |
| Average True Range (ATR) | 0.06 | 0.10 |
| MACD | 0.00 | -0.01 |
| Stochastic Oscillator | 44.83 | 33.33 |
Price Performance
Historical ComparisonAbout DOUG Douglas Elliman Inc.
Douglas Elliman Inc is engaged in the real estate services business and seeks to acquire or invest in additional real estate services businesses. The Company also offers, through its subsidiaries and ventures, development marketing services and ancillary services, including mortgage, title, and escrow services. It generates revenue from commissions and other brokerage income, property management, and other ancillary services.
About TLSA Tiziana Life Sciences Ltd.
Tiziana Life Sciences Ltd is a clinical-stage biotechnology company that specializes in developing transformative therapies for neurodegenerative and neuroinflammatory diseases. The company's clinical pipeline includes drug assets for Non-Active Secondary Progressive Multiple Sclerosis, Multiple System Atrophy, Alzheimer's, and Amyotrophic Lateral Sclerosis. The company's mission is to design and deliver next-generation immunotherapies for neurodegenerative and neuroinflammatory diseases. The company's main immunotherapeutic candidate, Foralumab (TZLS-401), is being developed for Non-Active Secondary Progressive Multiple Sclerosis, Alzheimer's, and other CNS indications.